S&P 500   4,074.67 (+1.66%)
DOW   32,587.22 (+1.13%)
QQQ   304.57 (+2.05%)
AAPL   148.26 (+1.87%)
MSFT   264.86 (+1.28%)
FB   201.74 (+0.85%)
GOOGL   2,321.92 (+1.44%)
AMZN   2,267.67 (+2.32%)
TSLA   757.51 (+4.58%)
NVDA   179.69 (+4.08%)
BABA   90.31 (+4.43%)
NIO   16.46 (+13.13%)
AMD   102.69 (+8.97%)
CGC   5.93 (+3.49%)
MU   73.75 (+4.65%)
T   20.49 (+1.04%)
GE   76.68 (+2.75%)
F   13.41 (+2.76%)
DIS   107.34 (+2.05%)
AMC   12.37 (+5.64%)
PFE   51.42 (+1.48%)
PYPL   78.71 (+1.37%)
NFLX   189.47 (+1.59%)
S&P 500   4,074.67 (+1.66%)
DOW   32,587.22 (+1.13%)
QQQ   304.57 (+2.05%)
AAPL   148.26 (+1.87%)
MSFT   264.86 (+1.28%)
FB   201.74 (+0.85%)
GOOGL   2,321.92 (+1.44%)
AMZN   2,267.67 (+2.32%)
TSLA   757.51 (+4.58%)
NVDA   179.69 (+4.08%)
BABA   90.31 (+4.43%)
NIO   16.46 (+13.13%)
AMD   102.69 (+8.97%)
CGC   5.93 (+3.49%)
MU   73.75 (+4.65%)
T   20.49 (+1.04%)
GE   76.68 (+2.75%)
F   13.41 (+2.76%)
DIS   107.34 (+2.05%)
AMC   12.37 (+5.64%)
PFE   51.42 (+1.48%)
PYPL   78.71 (+1.37%)
NFLX   189.47 (+1.59%)
S&P 500   4,074.67 (+1.66%)
DOW   32,587.22 (+1.13%)
QQQ   304.57 (+2.05%)
AAPL   148.26 (+1.87%)
MSFT   264.86 (+1.28%)
FB   201.74 (+0.85%)
GOOGL   2,321.92 (+1.44%)
AMZN   2,267.67 (+2.32%)
TSLA   757.51 (+4.58%)
NVDA   179.69 (+4.08%)
BABA   90.31 (+4.43%)
NIO   16.46 (+13.13%)
AMD   102.69 (+8.97%)
CGC   5.93 (+3.49%)
MU   73.75 (+4.65%)
T   20.49 (+1.04%)
GE   76.68 (+2.75%)
F   13.41 (+2.76%)
DIS   107.34 (+2.05%)
AMC   12.37 (+5.64%)
PFE   51.42 (+1.48%)
PYPL   78.71 (+1.37%)
NFLX   189.47 (+1.59%)
S&P 500   4,074.67 (+1.66%)
DOW   32,587.22 (+1.13%)
QQQ   304.57 (+2.05%)
AAPL   148.26 (+1.87%)
MSFT   264.86 (+1.28%)
FB   201.74 (+0.85%)
GOOGL   2,321.92 (+1.44%)
AMZN   2,267.67 (+2.32%)
TSLA   757.51 (+4.58%)
NVDA   179.69 (+4.08%)
BABA   90.31 (+4.43%)
NIO   16.46 (+13.13%)
AMD   102.69 (+8.97%)
CGC   5.93 (+3.49%)
MU   73.75 (+4.65%)
T   20.49 (+1.04%)
GE   76.68 (+2.75%)
F   13.41 (+2.76%)
DIS   107.34 (+2.05%)
AMC   12.37 (+5.64%)
PFE   51.42 (+1.48%)
PYPL   78.71 (+1.37%)
NFLX   189.47 (+1.59%)
NASDAQ:CBAY

CymaBay Therapeutics (CBAY) Stock Forecast, Price & News

$1.85
+0.06 (+3.35%)
(As of 05/17/2022 01:31 PM ET)
Add
Compare
Today's Range
$1.80
$1.88
50-Day Range
$1.72
$3.40
52-Week Range
$1.67
$5.06
Volume
18,142 shs
Average Volume
732,633 shs
Market Capitalization
$156.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.08
30 days | 90 days | 365 days | Advanced Chart
Receive CBAY News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CymaBay Therapeutics logo

About CymaBay Therapeutics

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CBAY
Employees
59
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$1.93 per share

Profitability

Net Income
$-90 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
80,021,000
Market Cap
$156.66 million
Optionable
Optionable

Company Calendar

Last Earnings
5/12/2022
Today
5/17/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.16 out of 5 stars

Medical Sector

401st out of 1,423 stocks

Pharmaceutical Preparations Industry

164th out of 678 stocks

Analyst Opinion: 3.6Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













CymaBay Therapeutics (NASDAQ:CBAY) Frequently Asked Questions

Is CymaBay Therapeutics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CymaBay Therapeutics stock.
View analyst ratings for CymaBay Therapeutics
or view top-rated stocks.

When is CymaBay Therapeutics' next earnings date?

CymaBay Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for CymaBay Therapeutics
.

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) issued its earnings results on Thursday, May, 12th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.01. During the same period in the previous year, the firm earned ($0.25) EPS.
View CymaBay Therapeutics' earnings history
.

What price target have analysts set for CBAY?

5 brokerages have issued 1-year price objectives for CymaBay Therapeutics' shares. Their forecasts range from $8.00 to $14.00. On average, they anticipate CymaBay Therapeutics' share price to reach $10.67 in the next twelve months. This suggests a possible upside of 475.0% from the stock's current price.
View analysts' price targets for CymaBay Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are CymaBay Therapeutics' key executives?
CymaBay Therapeutics' management team includes the following people:
  • Mr. Sujal A. Shah, Pres, CEO & Director (Age 49, Pay $820.57k)
  • Dr. Charles A. McWherter Ph.D., Chief Scientific Officer (Age 67, Pay $597.89k)
  • Mr. Paul T. Quinlan, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 59, Pay $578.82k)
  • Mr. Daniel Menold, VP of Fin. (Age 52)
  • Mr. Ken Boehm, Sr. VP of HR
  • Mr. Patrick J. O'Mara, Sr. VP of Bus. Devel. (Age 61)
  • Dr. Robert L. Martin, Sr. VP of Manufacturing & Nonclinical Devel. (Age 60)
  • Ms. Klara A. Dickinson-Eason, Chief Regulatory & Quality Assurance Officer (Age 54)
  • Ms. Becki Filice, Sr. VP of Portfolio & Product Leadership (Age 61)
  • Dr. Dennis D. Kim M.B.A., M.D., MBA, Chief Medical Officer (Age 52)
What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

Who are CymaBay Therapeutics' major shareholders?

CymaBay Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.46%), Vanguard Group Inc. (4.54%), Nantahala Capital Management LLC (2.24%), State Street Corp (1.60%), JPMorgan Chase & Co. (1.54%) and Affinity Asset Advisors LLC (1.50%).
View institutional ownership trends for CymaBay Therapeutics
.

Which institutional investors are selling CymaBay Therapeutics stock?

CBAY stock was sold by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, JPMorgan Chase & Co., Prosight Management LP, Invesco Ltd., GSA Capital Partners LLP, UBS Group AG, ClariVest Asset Management LLC, and HAP Trading LLC.
View insider buying and selling activity for CymaBay Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying CymaBay Therapeutics stock?

CBAY stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Affinity Asset Advisors LLC, Dimensional Fund Advisors LP, BlackRock Inc., Goldman Sachs Group Inc., Northern Trust Corp, Connor Clark & Lunn Investment Management Ltd., and Charles Schwab Investment Management Inc..
View insider buying and selling activity for CymaBay Therapeutics
or or view top insider-buying stocks.

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CymaBay Therapeutics' stock price today?

One share of CBAY stock can currently be purchased for approximately $1.86.

How much money does CymaBay Therapeutics make?

CymaBay Therapeutics has a market capitalization of $157.08 million. The biopharmaceutical company earns $-90 million in net income (profit) each year or ($1.330010) on an earnings per share basis.

How many employees does CymaBay Therapeutics have?

CymaBay Therapeutics employs 59 workers across the globe.

What is CymaBay Therapeutics' official website?

The official website for CymaBay Therapeutics is www.cymabay.com.

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at (510) 293-8800, via email at [email protected], or via fax at 510-293-9090.

This page was last updated on 5/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.